Non-Alcoholic Fatty Liver Diseases
The term "non-alcoholic fatty liver disease" (NAFLD) or "metabolic (dysfunction) associated fatty liver disease" (MAFLD) refers to an abnormal accumulation of fat in the liver that has no other obvious cause, such as alcohol consumption. There are 2 types: non-alcoholic steatohepatitis (NASH), which also causes liver inflammation, and non-alcoholic fatty liver (NAFL). Non-alcoholic fatty liver usually does not proceed to NASH and is less harmful than NASH. When NAFL eventually transforms into NASH, it may also bring on side effects like cirrhosis, liver cancer, liver failure, or cardiovascular disease.
Obesity and type 2 diabetes are strong risk factors for NAFLD. Other risks include being overweight, metabolic syndrome (defined as at least three of the five following medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum HDL cholesterol), a diet high in fructose, and older age. NAFLD and alcoholic liver disease are types of fatty liver disease. Obtaining a sample of the liver after excluding other potential causes of fatty liver can confirm the diagnosis.
Related Conference of Non-Alcoholic Fatty Liver Diseases
7th International Conference on Gastroenterology and Liver Diseases
24th International Conference on Gastroenterology and Digestive Disorders
26th International Conference on Gastroenterology and Hepatology
20th World Congress on Gastroenterology -Therapeutics & Hepatology
17th International Conference on Liver Diseases & Hepatology
Non-Alcoholic Fatty Liver Diseases Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Abdominal Health & Frontline Medicine - Gastrosummit 2025 (France)
- Advances in Gastrointestinal Cancer Management - Gastrosummit 2025 (France)
- Advances in Gastrointestinal Oncology - WORLD GASTROENTEROLOGY 2026 (Spain)
- Advances in Gastrointestinal Therapeutics - Gastroenterology – 2025 (France)
- Advances in GERD Treatment - WORLD GASTROENTEROLOGY 2026 (Spain)
- Advances in GI Endoscopy & Surgical Precision - Gastrosummit 2025 (France)
- Alcoholic Liver Disease: Emerging Treatments - WORLD GASTROENTEROLOGY 2026 (Spain)
- Barrett’s Esophagus: Current Therapeutics - WORLD GASTROENTEROLOGY 2026 (Spain)
- Celiac Disease and Gluten-Related Disorders - Gastroenterology – 2025 (France)
- Celiac Disease: Latest Treatment Options - WORLD GASTROENTEROLOGY 2026 (Spain)
- Colorectal Cancer: Prevention, Screening, and Treatment - Gastroenterology – 2025 (France)
- Diagnostic Biomarkers and Therapeutic Targets in Digestive Diseases - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Digestive System Cancers - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Disorders of the Small Bowel and Colon - Gastrosummit 2025 (France)
- Disorders of the Small Bowel and Colon - Gastrosummit 2025 (France)
- Emerging Therapies for Crohn's - WORLD GASTROENTEROLOGY 2026 (Spain)
- Endoscopic Innovations and Techniques - Gastroenterology – 2025 (France)
- Endoscopy and Minimally Invasive Gastrointestinal Procedures - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Esophageal and Gastric Disease - Gastrosummit 2025 (France)
- Esophageal Disorders: Current Treatments - WORLD GASTROENTEROLOGY 2026 (Spain)
- Functional GI Disorders: IBS and Beyond - Gastroenterology – 2025 (France)
- Gastroenterology - Gastrosummit 2025 (France)
- Gastrointestinal Cancer - Gastrosummit 2025 (France)
- Gastrointestinal Disorders and Treatment - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gastrointestinal Infections and Antimicrobial Resistance - Gastroenterology – 2025 (France)
- Gastrointestinal Infections and Immunity - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gastrointestinal Oncology and Tumor Biology - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gastrointestinal Oncology: From Screening to Targeted Therapies - Gastroenterology – 2025 (France)
- Gastrointestinal Pharmacotherapy - Gastrosummit 2025 (France)
- Gastrointestinal Stromal Tumors: Novel Therapies - WORLD GASTROENTEROLOGY 2026 (Spain)
- GI Oncology: Colorectal and Pancreatic Cancers - Gastroenterology – 2025 (France)
- Gut Microbiota and Gastrointestinal Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gut Microbiota and Metabolic Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Hepatic Encephalopathy: Modern Management Strategies - WORLD GASTROENTEROLOGY 2026 (Spain)
- Hepatitis C Therapeutics - WORLD GASTROENTEROLOGY 2026 (Spain)
- Hepatocellular Carcinoma: Latest Approaches - WORLD GASTROENTEROLOGY 2026 (Spain)
- Hepatology - Gastrosummit 2025 (France)
- Hepatology: Liver Disease and Transplantation - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Impact of COVID-19 on Gastroenterology Practice - Gastrosummit 2025 (France)
- Inflammatory Bowel Disease (IBD): Crohn’s and Ulcerative Colitis - Gastroenterology – 2025 (France)
- Inflammatory Bowel Disease (IBD): Insights and Advancements - Gastroenterology – 2025 (France)
- Inflammatory Bowel Disease and Intestinal Inflammation - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Inflammatory Bowel Diseases - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Innovations in IBD Management - WORLD GASTROENTEROLOGY 2026 (Spain)
- Insights into Celiac Disease - Gastrosummit 2025 (France)
- Insights into Celiac Disease - Gastrosummit 2025 (France)
- Insights into Gastrointestinal Pathology - Gastrosummit 2025 (France)
- Liver and Pancreatic Disorders - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Liver Cirrhosis and Complications - Gastroenterology – 2025 (France)
- Liver Cirrhosis: New Therapies - WORLD GASTROENTEROLOGY 2026 (Spain)
- Liver Diseases and Hepatic Disorders - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Liver Diseases and Hepatology - Gastroenterology – 2025 (France)
- Microbiome and Gastrointestinal Health - WORLD GASTROENTEROLOGY 2026 (Spain)
- Microbiome and Gut Health - Gastroenterology – 2025 (France)
- NAFLD and NASH Treatments - WORLD GASTROENTEROLOGY 2026 (Spain)
- New Approaches to Peptic Ulcer Disease - WORLD GASTROENTEROLOGY 2026 (Spain)
- Non-Alcoholic Fatty Liver Disease - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH - Gastroenterology – 2025 (France)
- Nutrition and Aging: Geriatric Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Paediatric Gastroenterology - Gastrosummit 2025 (France)
- Pancreatic and Biliary Disease - Gastrosummit 2025 (France)
- Pancreatitis: Modern Therapeutic Strategies - WORLD GASTROENTEROLOGY 2026 (Spain)
- Pediatric and Adolescent Nutrition - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Pediatric Gastroenterology and Nutrition - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Pediatric Gastroenterology: Challenges and Innovations - Gastroenterology – 2025 (France)
- Peptic Ulcer and Acid-related Disorders - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Peptic Ulcer Disease and H. pylori Infection - Gastroenterology – 2025 (France)
- Plant-Based Nutrition and Sustainable Diets - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Role of Microbiota in Digestive Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- The Microbiota Universe - Gastrosummit 2025 (France)
- Therapeutics for Biliary Diseases - WORLD GASTROENTEROLOGY 2026 (Spain)
- Ulcerative Colitis: Innovative Treatments - WORLD GASTROENTEROLOGY 2026 (Spain)
- Viral Hepatitis: New Treatment Paradigms - WORLD GASTROENTEROLOGY 2026 (Spain)